CALT News and Press, Calliditas Therapeutics AB From 01/19/21

Calliditas Therapeutics' ([[CALT]] +6.4%) subsidiary Genkyotex has announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset.The study in 46 healthy volunteers demonstrated that setanaxib is well tolerated ...

Positive Phase 1 results in high-dose setanaxib trial PR Newswire STOCKHOLM , Jan. 18, 2021 /PRNewswire/ -- Genkyotex SA, a subsidiary of Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT), today announced positive Phase 1 data...

Agenda for Calliditas virtual R&D Day on January 20, 2021 Agenda for Calliditas virtual R&D Day on January 20, 2021 PR Newswire STOCKHOLM , Jan. 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX) (NASDAQ...

Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex STOCKHOLM , Dec. 16, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) submitted a simplified public mandatory offe...

Calliditas wins the 2020 SwedenBio Award STOCKHOLM , Dec. 10, 2020 /PRNewswire/ -- The winner of this year's SwedenBIO Award was announced on Wednesday December 9 th . Calliditas Therapeutics AB (publ) ("Calliditas") received the award in recognition of its suc...

Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021 STOCKHOLM , Dec. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the company will host a Capital Markets Day in Stockholm, ...

SHANGHAI, China, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, ...

Calliditas Therapeutics' nomination committee for the AGM 2021 PR Newswire STOCKHOLM, Nov. 27, 2020 STOCKHOLM , Nov. 27, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021. ...

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion...

Calliditas Therapeutics (CALT): Q3 GAAP EPS of -SEK2.77.Cash of SEK1.4BPress Release For further details see: Calliditas Therapeutics reports Q3 results